[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-diseases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,48,83,120,145,182,213,236,261,286,309,331,352,376,404,425,451,480,504,536,557,582,605,629,654],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645190","immersive-virtual-reality-applied-to-therapeutic-physical-exercise-in-cellular-therapy-100645190",false,"NCT07679958","Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy","RVI-ET","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Signed informed consent.\n* Patients eligible for CT scan at the Alvaro Cunqueiro Hospital.\n* Patients capable of performing therapeutic exercise independently, based on an objective initial functional assessment.\n* The clinical investigator, in their professional judgment, determines that the patient can adhere to all study requirements.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Any medical condition or mental illness that could interfere with understanding HIP and CI.\n* Patients participating in another clinical trial.\n* Balance disorders that increase the risk of falls.\n* Severe visual and\u002For auditory impairments that prevent participation in the session.\n* History of vertigo, seizures, or epileptic fits.","ALL","18 Years",{"count":19,"type":20},144,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cell therapy (CT), including hematopoietic stem cell transplantation (HSCT) and advanced CAR T-cell therapies, is used for the treatment of oncohematological and other diseases. HSCT is associated with treatment-related toxicities, including fatigue, muscle weakness, and reduced functional capacity due to intensive conditioning chemotherapy, immunosuppressive treatments, corticosteroids, and complications such as infections or graft-versus-host disease. Emotional symptoms, including anxiety, depression, fear, and frustration, also affect patients' recovery and ability to regain functional independence. Evidence indicates that exercise interventions improve emotional well-being, fatigue, quality of life, physical function, cardiovascular fitness, and muscle mass in patients with hematological malignancies and HSCT recipients.\n\nVirtual reality (VR) has emerged as an innovative tool in rehabilitation, supporting patient motivation, exercise guidance, and monitoring. Immersive virtual reality (IVR), through head-mounted displays and multisensory environments, enhances the sense of presence and engagement. Studies suggest that IVR-based exercise programs are feasible, improving functional abilities, quality of life, satisfaction, and adherence.\n\nSince 2017, a Therapeutic Exercise program for patients admitted for HSCT has been implemented at Álvaro Cunqueiro Hospital (Vigo) through collaboration between the Physiotherapy Unit and the Hematology Department. Before admission, patients undergo a physical assessment, receive an individualized exercise plan, education, and a therapeutic exercise guide. Based on clinical experience, the team hypothesizes that integrating IVR into therapeutic exercise may improve motivation, adherence, and emotional well-being during hospitalization.",[26,27,28,29,30],"Hematologic Diseases","Hematopoietic Stem Cell Transplantation","Cellular Therapy","Quality of Life","Oncologic Disorders",[32,33,34],"Therapeutic Exercise","Immersive virtual reality","Cellular therapy","NOT_YET_RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":20},"2026-07-24",{"date":43,"type":20},"2029-06-01",{"name":45,"class":46},"Fundacin Biomedica Galicia Sur","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100622725","phase-1-pacritinib-with-aza-for-upfront-myelodysplastic-syndrome-100622725","NCT07387354","Pacritinib With Aza for Upfront Myelodysplastic Syndrome","A Phase 1\u002F2 Study of Pacritinib in Combination With Azacitidine for the Treatment of IPSS-M Moderate Low to Very High Risk Myelodysplastic Syndrome","MDS","Inclusion Criteria:\n\n* Individuals must meet all of the following inclusion criteria to be eligible to participate in the study:\n\n  1. Patients must have histologic evidence of intermediate to high-risk myelodysplastic syndrome defined as having an IPSS-M score of moderate low, moderate high, high or very high risk. This will be assessed based on evaluations performed prior to screening for trial. Of note, the most recent evaluation pre-trial may be used which does not have to necessarily be at diagnosis.\n  2. Subjects must have recovered from the toxic effects of any prior chemotherapy to ≤ Grade 1 (except alopecia).\n  3. Required screening visit laboratory values: CrCL ≥45; total bilirubin \\\u003C2xULN except for patients with known Gilbert's disease; SGPT (ALT) ≤2xULN, PTT ≤1.5xULN.\n  4. Negative pregnancy test for women with child-bearing potential at screening visit.\n  5. Initial screening baseline QTc ≤480ms.\n  6. Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.\n  7. Patients must have an absolute neutrophil count of ≥750 to enroll in study, this must be achieved without the addition of growth factor medication.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Any prior exposure to a hypomethylating agent (azacitidine or decitabine)\n  2. Any prior exposure to JAK2 inhibitor therapy (ie ruxolitinib or prior pacritinib therapy)\n  3. Any exposure within the past seven days of initiation of study treatment to a strong CYP3A inhibitor\u002Finducer.\n  4. Subjects must not be receiving any chemotherapy agents (except hydroxyurea) within the past thirty days.\n  5. Subjects must not be receiving growth factors (erythropoietin mimetics, granulocyte stimulating factor mimetics, thrombopoietin mimetics) for two weeks prior to enrollment bone marrow. Subjects may not receive growth factors for the duration of this study.\n  6. Subjects with a \"currently active\" second malignancy, other than curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pT2 with Gleason Score ≤ 6 and postoperative PSA \\\u003C0.5 ng\u002FmL), or other adequately treated carcinoma-in-situ are eligible. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 1 year.\n  7. Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure (NYHA class 2), myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.\n  8. Bleeding event grade \\>=2 (CTCAE 5.0) within prior three months unless provoked (e.g., by surgery or trauma)\n  9. Use of anticoagulant or antiplatelet agents within fourteen days prior to day one with the exception of low dose aspirin (81mg daily).\n  10. Subjects with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.\n  11. Active or uncontrolled diarrhea or constipation.\n  12. Subjects must not have evidence of active disease in the CNS.\n  13. Subjects must not have received any investigational agents within fourteen days or five half-lives (whichever is longer) of study entry.\n  14. Subjects must not be pregnant or breastfeeding. Pregnancy tests must be obtained for all females of child-bearing potential. Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of pacritinib. Males or women of childbearing potential may not participate unless they have agreed to use a highly effective contraceptive method (defined in section 10.4.4).\n  15. Subjects who have uncontrolled infection are not eligible. Patients must have any active infections under control. Fungal disease must be stable for at least two weeks before study entry.\n  16. Subjects with bacteremia must have documented negative blood cultures prior to study entry.\n  17. Subjects who are currently candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation prior to study start.\n  18. Subjects who cannot hold a medication, over the counter, or supplemental product that in the investigator's opinion may put the patient at increased harm.",{"count":5,"type":20},[58,59],"PHASE1","PHASE2","This study will be conducted as a phase 1\u002F2 study of safety and preliminary efficacy of pacritinib in combination with azacitidine for IPSS-M moderate low to very high risk MDS. Phase one will be a 3 + 3 design to assess the dose for the phase two portion. The phase two portion will employ a simon min-max two-stage design whereby fifteen patients will be enrolled in the first stage then ten more if at least two patients in stage one have a response. The dosing of pacritinib for the phase two study will be based on the phase one findings. Standard dosing of azacitidine will be used. A correlative study will be conducted in conjunction with the trial where the investigators will measure whole blood collected pre-treatment and at four days post-treatment to measure intracellular flow and phosflow to detect JAK\u002FSTAT, NF-κβ, and AKT\u002FmTOR signaling in patient samples and how treatment affects these pathways.",[62,54,63,26,64,65],"Myelodysplastic Syndromes","Myelodysplastic Syndrome, Unclassifiable","Bone Marrow Disease","Myeloproliferative Neoplasm",[67,68,69,70,71,72,73],"Pacritinib","Azacitidine","IPSS-M","JAK\u002FSTAT","JAK\u002FIRAK1","NF-κβ","Myelodysplastic Syndrome","2026-06-08",{"date":76,"type":39},"2026-06-10",{"date":78,"type":20},"2026-07",{"date":80,"type":20},"2027-01",{"name":82,"class":46},"Thomas Jefferson University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":47},"100577247","the-implementation-of-the-go-wish-game-to-promote-advance-care-planning-in-onco--hematologic-disease-100577247","NCT06795815","The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease","The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco-hematologic Disease (Onco-hema Go Wish-ACP): Intervention Set up and Multicentre Feasibility Trial","OHGW-ACP","Inclusion Criteria:\n\n* ≥ 18 years age; diagnosed with refractory lymphomas, or leukemia or multiple myeloma or advanced solid tumors and estimated prognosis \\> 3 months;\n* able to communicate in Italian and\n* to give written consent to the study.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or serious psychiatric condition;\n* refusal to participate to the study","99 Years",{"count":93,"type":20},75,[23],"This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation.\n\nThe GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life.\n\nThe \"Onco-hema Go wish-ACP\" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis \\> 3 months.\n\nIn terms of secondary objectives, the study aims to.\n\n* Evaluate and compare the intervention with hematology and oncology patients in terms of: - Other feasibility indicators; Involvement in CCP pathways; Quality of communication; Meaning of life; Impact on hope; through a series of questionnaires administered to patients and caregivers involved in the intervention\n* Qualitatively assess the acceptability of the intervention in terms of recruitment and delivery with patients and caregivers through semi-structured interviews and with professionals through Focus Groups (FGs).\n* To analyze the clinical records of enrolled patients in terms of: values and preferences; awareness of prognosis; end-of-life choices and shared decision-making on treatment decisions.",[97,98,99,100,101,26],"Leukemia","Multiple Mieloma","Advanced Solid Tumors","Lymphoma","Oncology",[103,104,105,106,101,107,108,109],"Advance Care Planning","Go Wish Game","Medical Oncology","Hematology","Palliative Care","Experimental Design Study","Mixed Methods","RECRUITING","2026-05-04",{"date":113,"type":39},"2026-05-07",{"date":115,"type":39},"2025-06-30",{"date":78,"type":20},{"name":118,"class":119},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":47},"100471067","autologous-testicular-tissue-transplantation-100471067","NCT05414045","Autologous Testicular Tissue Transplantation","Autologous Testicular Tissue Transplantation for Fertility Restoration","The eligible patients opted as a prepubertal boy to enroll in the fertility preservation program and on the moment of cancer diagnosis or hematological disorder, their parents have agreed to cryopreserve testicular tissue for later autologous transplantation.\n\nInclusion Criteria:\n\n* At least 18 years old\n* In case of female partner, age \\\u003C 43 year\n* Absence of spermatozoa that can be used for ICSI on 2 semen analyses\n* Normal standardised preliminary and preoperative bloodsampling results\n* Complete remission of the oncological or hematological disease\n* Approval of the treating oncologist or other specialist in case of non-oncological disease as reason for the testicular tissue preservation as a child\n* Risk for presence of malignant cells in testicular tissue is negligible (according to multidisciplinary assessment)\n* Presence of spermatogonial stem cells (positive MAGE staining) in one or two of the thawed fragments (If absence of spermatogonial stem cells in two of the thawed fragments, the case will be discussed multidisciplinary)\n* Written informed consent for the transplantation of cryopreserved testicular tissue and follow-up after the procedure and of children born eventually after this procedure\n\nExclusion criteria:\n\n* Risk for presence of malignant cells in the testicular tissue\n* Contra-indication for surgery\n* Contra-indication for pregnancy in the female partner\n* BMI \\> 32\n* Heavy smoking (≥10 cigarettes\u002Fday)\n* Instable psychological condition","MALE","50 Years",{"count":130,"type":20},5,[23],"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells in case of imminent gonadotoxic treatment during childhood. In case of total azoospermia or absence of spermatozoa that can be used for intra-cytoplasmic injection (ICSI) in adulthood, the investigators intend to perform the first in men autologous testicular tissue transplantation to restore fertility.",[134,135,26],"Cancer","Sickle Cell Thalassemia","2026-04-20",{"date":138,"type":39},"2026-04-23",{"date":140,"type":39},"2024-11-22",{"date":142,"type":20},"2030-10-29",{"name":144,"class":46},"Universitair Ziekenhuis Brussel",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":47},"100513772","clonal-hematopoiesis-of-immunological-significance-100513772","NCT05969821","Clonal Hematopoiesis of Immunological Significance","Immuno-inflammatory Manifestations With or Without Clonal Hematopoiesis: Ambispective Cohort Study","CHIS","Inclusion Criteria:\n\n* Age \\>=18 years old;\n* Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease;\n* Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification\n\nExclusion Criteria:\n\n* Persons benefiting from special protection: adults under guardianship and curatorship;\n* People hospitalized without their consent and not protected by law; persons deprived of liberty;\n* Persons not affiliated to the social security system",{"count":154,"type":20},5000,"10 Years","OBSERVATIONAL","Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.",[159,160,161,162,163,164,165,26,166,167,62,168,169,100,97,170],"Immune System Diseases","Autoimmune Diseases","Inflammation","Autoinflammatory Diseases","Vexas Syndrome","Hematopoiesis Clonal","Clonal Hematopoiesis of Indeterminate Potential","Myelodysplastic-Myeloproliferative Diseases","Leukemia Myelomonocytic Chronic","Myeloproliferative Disorders","Lymphoproliferative Disorders","Monoclonal Gammopathy of Undetermined Significance",[161,162,172,160,165,166,169,170],"Vexas syndrome","2026-03-19",{"date":175,"type":39},"2026-03-23",{"date":177,"type":20},"2026-04",{"date":179,"type":20},"2045-09",{"name":181,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":212},"100475948","phase-3-evaluation-of-efficacy-and-safety-of-a-single-dose-of-ctx001-in-participants-with-transfusion-dependent--thalassemia-and-severe-sickle-cell-disease-100475948","NCT05477563","Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease","Key Inclusion Criteria:\n\n* Participants with TDT and SCD:\n* Eligible for autologous stem cell transplant as per investigator's judgment.\n* Participants with TDT:\n* Diagnosis of TDT as defined by:\n* Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia\u002Fhemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning\n* History of at least 100 milliliter (mL)\u002Fkilograms (kg)\u002Fyear or 10 units\u002Fyear of packed red blood cells (RBC) transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening\n* Participants with SCD:\n* Diagnosis of severe SCD as defined by:\n* Documented SCD genotypes\n* History of at least two severe VOCs events per year for the previous two years prior to enrollment\n\nKey Exclusion Criteria:\n\n* Participants with TDT and SCD:\n* A willing and healthy 10\u002F10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement\n* Prior hematopoietic stem cell transplant (HSCT)\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator\n* Participants with TDT:\n* Participants with associated α-thalassemia and \\>1 alpha deletion, or alpha multiplications\n* Participants with sickle cell β-thalassemia variant\n* Participants with SCD:\n* History of untreated moyamoya syndrome or presence of moyamoya syndrome at screening\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","12 Years","35 Years",{"count":192,"type":20},26,[194],"PHASE3","This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.",[197,198,26,199,200,201,202],"Beta-Thalassemia","Thalassemia","Genetic Diseases, Inborn","Hemoglobinopathies","Sickle Cell Disease","Sickle Cell Anemia","2026-03-18",{"date":175,"type":39},{"date":206,"type":39},"2022-08-02",{"date":208,"type":20},"2027-06-09",{"name":210,"class":211},"Vertex Pharmaceuticals Incorporated","INDUSTRY",6,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":47},"100411702","phase-1-stem-cell-transplant-from-donors-after-alpha-beta-cell-depletion-in-children-and-adults-with-t-allo10-cells-addback-100411702","NCT04640987","Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback","Phase 1\u002F1b Study of T-allo10 Infusion After HLA-Partially Matched Related or Unrelated TCR αβ+ T-cell\u002F CD19+ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (αβ Depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies","Inclusion Criteria prior to enrollment:\n\n* 1\\. Age \\> 1 months (with minimum weight of 10 Kg) and \\\u003C 45 years.\n* 2\\. Patients deemed eligible for allogeneic HSCT under the originating study, NCT 04249830\n* 3\\. Patients with life-threatening hematological malignancies for which HSCT has been recommended:\n\n  1. High-risk ALL in 1st CR, ALL in 2nd or subsequent CR;\n  2. High-risk AML in 1st CR, AML in 2nd or subsequent CR;\n  3. Myelodysplastic syndrome;\n  4. JMML (Juvenile myelomonocytic leukemia);\n  5. Non-Hodgkin lymphomas in 2nd or subsequent CR;\n  6. Other hematologic malignancies eligible for stem cell transplantation per institutional standard.\n* 4\\. All subjects ≥ 18 years of age must be able to give informed consent, or adults lacking capacity to consent must have a LAR available to provide consent. For subjects \\\u003C18 years old their LAR (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those \\> 7 years of age, when appropriate.\n\nInclusion criteria prior to T-allo10 infusion:\n\n1. Patient already received αβdepleted-HSCT and has myeloid engraftment.\n2. Absence of active grade II aGvHD requiring \\>0.5 mg\u002FKg of steroids or any diagnosis of grade III\u002FIVaGvHD.\n\nExclusion Criteria prior to MNC collection for Tallo-10 manufacturing.:\n\n1. Not eligible to receive HSCT on NCT04249830\n2. Received another investigational agent within 30 days of enrollment.\n3. Pregnancy (positive serum or urine beta-HCG) within 7 days of MNC donation.\n4. Patient or donor is not willing or able to undergo an additional non-mobilized apheresis for collection of MNC prior to donation of cells for participation in NCT04249830.","1 Month","45 Years",{"count":223,"type":20},22,[58],"The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD).\n\nThe primary objective of Phase 1a is to determine the recommended Phase 2 dose (RP2D) administered after infusion of αβdepleted-HSCT in children and young adults with hematologic malignancies.\n\nA Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10 cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of T-allo10 after receipt of αβdepleted-HSCT. Additionally, Phase 1b aims to explore improvements in immune reconstitution.\n\nAll participants on this study must be enrolled on another study: NCT04249830",[26],"2026-01-06",{"date":229,"type":39},"2026-01-08",{"date":231,"type":39},"2021-02-10",{"date":233,"type":20},"2029-03",{"name":235,"class":46},"Porteus, Matthew, MD",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":47},"100612750","phase-1-il-5-car-t-cell-therapy-for-refractoryrelapsed-eosinophilic-leukemia-100612750","NCT07257640","IL-5 CAR-T Cell Therapy for Refractory\u002FRelapsed Eosinophilic Leukemia","The Safety and Efficay Investigation of IL-5 CAR-T Cell Therapy for Patients With Refractory\u002FRelapsed Eosinophilic Leukemia","Inclusion Criteria:\n\n* 1.Male or female patients aged ≥18 years;\n* 2.Diagnosis of eosinophilic leukemia (EL) established according to the WHO 2022 diagnostic criteria;\n* 3.Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts.\n* 4.Meet any of the following criteria for refractory\u002Frelapsed eosinophilic leukemia:\n* a) Inadequate response to standard therapy: failure to achieve complete remission (CR) after standard treatments (e.g., imatinib, corticosteroids, interferon-α, chemotherapy, etc.);\n* b) Disease progression\u002Frelapse within 6 months after achieving remission;\n* 5.Serum total bilirubin ≤1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN;\n* 6.Left ventricular ejection fraction (LVEF) \\>50% as assessed by echocardiography;\n* 7.Peripheral oxygen saturation (SpO₂) ≥92% on room air (without supplemental oxygen);\n* 8.Estimated life expectancy \\>3 months;\n* 9.Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* 10.Women and men of childbearing potential must agree to use appropriate, effective contraception prior to study entry, throughout the study period, and for 6 months after cell infusion (the safety of this therapy for unborn children is unknown and may pose potential risks);\n* 11.Patients who are willing to participate in this study and who are able to understand and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* 1.History of epilepsy or other central nervous system (CNS) disorders;\n* 2.Presence of any of the following:Hepatitis B surface antigen (HBsAg)-positive; Any of HBeAg, HBeAb, or HBcAb positive and detectable hepatitis B virus (HBV) DNA in peripheral blood above the lower limit of detection; Hepatitis C virus (HCV) antibody-positive; Human immunodeficiency virus (HIV) antibody-positive; Positive serologic test for syphilis;\n* 3.History of QT interval prolongation or severe cardiac disease;\n* 4.Presence of uncontrolled active infection;\n* 5.Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the interpretation of the study results.",{"count":244,"type":20},20,[58],"This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.",[26,248],"Neoplasms",[250,251],"IL-5 CAR-T","Eosinophil","2025-12-03",{"date":254,"type":39},"2025-12-10",{"date":256,"type":20},"2025-11-30",{"date":258,"type":20},"2028-11-30",{"name":260,"class":46},"Zhejiang University",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":270,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100553527","heme-home-transfusion-program-100553527","NCT06487247","HEME Home Transfusion Program","Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial","Inclusion Criteria for Patient Participants:\n\n* Diagnosis of a relapsed\u002Frefractory hematologic malignancy\n* Age ≥ 18 years\n* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)\n* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction\n* Patient resides within catchment served by Care Dimensions Hospice\n* Physician-estimated prognosis of six months or less\n\nInclusion Criteria for Caregivers:\n\n* Identified informal caregiver of enrolled patient with hematologic malignancy\n* Age ≥ 18 years\n\nExclusion Criteria for Patient Participants:\n\n* Age \\\u003C 18 years\n* Already enrolled in hospice\n* Resides in nursing home or assisted living facility\n* History of previous serious adverse transfusion reaction\n\nExclusion Criteria for Caregivers:\n\n-Age \\\u003C 18 years",{"count":269,"type":20},700,[23],"This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.",[97,273,62,274,26,100],"Myeloma","Hematologic Malignancy",[97,273,62,274,26,100],"2025-09-15",{"date":278,"type":39},"2025-09-17",{"date":280,"type":39},"2025-09-10",{"date":282,"type":20},"2029-05-31",{"name":284,"class":46},"Dana-Farber Cancer Institute",2,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":298,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":47},"100502867","phase-1-cd7-car-t-bridging-to-allohsct-for-rr-cd7malignant-hematologic-diseases-100502867","NCT05827835","CD7 CAR-T Bridging to alloHSCT for R\u002FR CD7+Malignant Hematologic Diseases","A Study to Evaluate the Efficacy and Safety of CD7CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed CD7 Positive Malignant Hematologic Diseases","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form (ICF)\n* Male or female, older than 18 years (including 18 years)\n* Anticipated survival time more than 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n* According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphocytic Leukemia and Acute Myeloid Leukemia (2016. v1), patients diagnosed as CD7+ALL and AML\n* Consistent with r\u002Fr CD7+acute leukemia diagnosis, including any of the following conditions\n* a. No CR after standard chemotherapy\n* b. The first induction reaches CR, but CR ≤ 12 months\n* c. Patients with r\u002Fr CD7+acute leukemia have not responded to the first or multiple remedial treatments\n* d. Multiple recurrences\n* Philadelphia chromosome negative (Ph -) subjects; Or cannot tolerate tyrosine kinase inhibitor (TKI) treatment; Or Philadelphia chromosome positive (Ph+) subjects who did not respond to both TKI treatments\n* Normal lung function, oxygen saturation greater than 92% without oxygen inhalation\n* The blood biochemical test results are consistent with the following results\n* a. (AST) and (ALT) ≤ 2.5 × (ULN)\n* b. Total bilirubin ≤ 1.5 × ULN\n* c. 24-hour serum creatinine clearance ≥ 30 mL\u002Fmin\n* d. Lipase and amylase ≤ 2 × ULN\n* Fertility capable men and women of childbearing age must agree to use effective contraception starting with the signing of an informed consent form until within 2 years after the use of the study drug. Women of reproductive age include pre menopausal women and women within 2 years after menopause. The blood pregnancy test for women of reproductive age must be negative at screening\n\nExclusion Criteria:\n\n* Patients with the history of epilepsy or other CNS disease\n* Pregnant or breastfeeding\n* Active infection with no cure\n* Patients with prolonged QT interval time or severe heart disease\n* Have experienced hypersensitivity or intolerance to any drug used in this study\n* Patients who received anticancer chemotherapy or other drug treatment within 2 weeks before screening\n* Previous malignant tumors that require treatment or have evidence of recurrence within the previous 5 years of screening\n* Clinically significant central nervous system lesions such as seizures, cerebral vascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, psychosis, active central nervous system involvement, or cancerous meningitis\n* In the past 2 years, terminal organ damage caused by autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) or the need for systematic application of immunosuppressive or other systemic disease control drugs\n* Severe active viral, bacterial, or uncontrolled systemic fungal infections; Genetic bleeding\u002Fcoagulation disorders, a history of non-traumatic bleeding or thromboembolism, and other diseases that may increase the risk of bleeding\n* Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening, or who plan to undergo ASCT during this study\n* Participated in clinical trials of other drugs within 4 weeks or 5 drug half-lives (T1\u002F2) before screening\n* Any situation that the researchers believe may increase the risk of patients or interfere with the test results.",{"count":294,"type":20},30,[58,59],"This is a single-arm, open-label, single-center, phase I\u002FII study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases",[26,248],[299,300],"allo-HSCT","CD7 CAR-T","2025-08-07",{"date":303,"type":39},"2025-08-13",{"date":305,"type":39},"2023-04-30",{"date":307,"type":20},"2027-04-25",{"name":260,"class":46},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":220,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":47},"100381686","stem-cell-transplant-from-donors-after-alpha-beta-cell-depletion-in-children-and-young-adults-100381686","NCT04249830","Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults","Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Related or Unrelated Donor After TCR αβ+T Cells\u002FCD19+ B Cell Depletion in Children and Young Adults Affected by Malignant or Non-Malignant Hematological Disorders","Inclusion Criteria for Cohort M and Cohort NM:\n\n1. Age \\\u003C 60 years and \\> 1 month;\n2. Life expectancy \\> 10 weeks;\n3. Patients deemed eligible for allogeneic HSCT per institutional guidelines;\n4. Patients with life-threatening hematological malignancies and non-malignant disorders that could benefit from HSCT;\n\n   a. For malignant patients: i. High-risk acute lymphoblastic leukemia (ALL) in 1st complete remission (CR), ALL in 2nd CR; or ii. High-risk acute myeloid leukemia (AML) in 1st CR, AML in 2nd CR; or iii. Childhood Myelodysplastic Syndrome (MDS) with low blasts (cMDS-LB) or Childhood MDS with increased blasts (cMDS-IB); or iv. Juvenile myelomonocytic leukemia (JMML); or v. Mixed-phenotype acute leukemia (MPAL); or vi. Non-Hodgkin lymphomas in 2nd CR; or vii. Other hematologic malignancies in 1st or 2nd CR eligible for stem cell transplantation per institutional standard b. Patients with non-malignant disorders receiving first HSCT: i. using mis-matched donors, due to the absence of suitable HLA identical sibling or HLA phenotypically identical relative; or ii. whose disease put them at increased risk of graft rejection or GvHD (e.g., Fanconi Anemia, STAT1 gain of function) and therefore can benefit from receiving alpha beta depleted HSCT using as a donor either an HLA identical sibling or an HLA phenotypically identical (10\u002F10 matched) donor;\n5. A minimum genotypic identical match of 5\u002F10 is required;\n6. The donor and recipient must be identical, as determined by high resolution typing, in at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DQB1 and HLA-DRB1;\n7. Lansky\u002FKarnofsky score \\> 50; the Karnofsky Scale will be used in subjects ≥ 16 years of age, and the Lansky Scale will be used for those \\\u003C 16 years of age.\n8. All subjects ≥ 18 years of age must be able to give informed consent or adults lacking capacity to consent must have a legally authorized representative (LAR) available to provide consent. For subjects \\\u003C18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and written assent will be obtained for those \\> 7 years of age, when appropriate\n9. Male and female subjects of childbearing potential must agree to use an effective means of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHD.\n\nExclusion Criteria for Cohort M and Cohort NM:\n\n1. Pregnant or lactating females;\n2. Has received a prior allogenic HSCT;\n3. Secondary MDS or AML or treatment related MDS or AML;\n4. Dysfunction of liver (ALT\u002FAST \\> 10 times upper normal value, or direct bilirubin \\> 3 times upper normal value),\n5. Serum creatinine \\> 1.5 times ULN (for patients not on dialysis) or unmanageable dysfunction of renal function while undergoing dialysis (for patients on dialysis);\n6. Severe cardiovascular disease (congestive heart failure or left ventricular ejection fraction \\\u003C 30%);\n7. Current active infectious disease (including positive HIV serology or viral RNA);\n8. Serious concurrent uncontrolled medical disorders;\n9. Lack of patient's\u002Fparents'\u002Fguardian's informed consent;\n10. Any severe concurrent disease which, in the judgement of the PI, would place the patient at increased risk during participation in the study.","60 Years",{"count":318,"type":20},204,[23],"The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy. Initially this device will be used in a single-center, open-label, single-arm, phase II clinical trial to evaluate the efficacy of haploidentical PBSC grafts depleted of TCRα\u002Fβ+ and CD19+ cells using the CliniMACS® TCRαβ\u002FCD19 System in children and adults with hematological and non-hematological malignancies.",[26],"2025-05-22",{"date":324,"type":39},"2025-05-29",{"date":326,"type":39},"2020-02-01",{"date":328,"type":20},"2030-12",{"name":330,"class":46},"Alice Bertaina",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":339,"conditions":340,"keywords":341,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":47},"100533157","the-use-of-residual-de-identified-specimens-andor-samples-from-patients-for-clinical-research-100533157","NCT06222164","The Use of Residual De-identified Specimens and\u002For Samples From Patients for Clinical Research","Inclusion Criteria:\n\n1. Specimen\u002Fsample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and\u002For formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens\u002Fsamples have been sent to LabPMM for clinical testing\n2. Donor Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Sample\u002Fspecimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM\n2. The specimens\u002Fsamples have previously been enrolled in a clinical study",{"count":338,"type":20},2000,"Acquire residual human specimens and\u002For samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research",[26],[342],"residual samples hematologic diseases","2025-05-02",{"date":345,"type":39},"2025-05-04",{"date":347,"type":39},"2024-03-30",{"date":349,"type":20},"2027-06-30",{"name":351,"class":211},"Invivoscribe, Inc.",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":47},"100468312","continuous-wireless-monitoring-of-vital-signs-and-automated-alerts-in-participants-at-home-and-during-hospitalization-100468312","NCT05378139","Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","WARD Prospective Study - Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","Inclusion Criteria:\n\n* Adult participants (≥18 years)\n* Patients assessed by the clinical staff as having an acute condition with risk for clinical deterioration and being either at home (with no apparent need for hospitalization), and\u002For in hospital OR\n* Patients at either at home before, in-hospital and\u002For after hospitalization for elective major surgery, defined as surgery lasting more than one hour under general- or regional anaesthesia\n\nExclusion Criteria:\n\n* The participant expected not to cooperate with study procedures.\n* Allergy to plaster or silicone.\n* Having pacemaker or Implantable Cardioverter Defibrillator (ICD) device.\n* Inability to give informed consent.",{"count":360,"type":20},3095,"The primary aim of this study is to test and assess the implementation and effectiveness of continuous wireless vital signs monitoring with real-time alerts on:\n\nThe frequency of patients monitored with adequate data quality as adequate clinical user satisfaction in the initial versus the last part of the trial (primary outcome).",[363,364,26,101,365,366],"Surgical Complication","Pulmonary Disease","Cardiac Disease","Infections","2025-04-08",{"date":369,"type":39},"2025-04-11",{"date":371,"type":39},"2021-02-01",{"date":373,"type":20},"2025-12-22",{"name":375,"class":46},"University Hospital Bispebjerg and Frederiksberg",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":403},"100552799","study-on-the-clinical-efficacy-of-teclistamab-100552799","NCT06477783","Study on the Clinical Efficacy of Teclistamab","Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium","TECTONIC","Inclusion Criteria:\n\n* Age 18 years or older\n* Written informed consent\n* Has a diagnosis of relapsed and refractory multiple myeloma\n* Has already received at least three previous treatments\n* Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody\n* Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria\n* Anticipated to start treatment with teclistamab per routine clinical care or has started with teclistamab treatment ≤14 days before intended screening visit\n\nExclusion Criteria:\n\n* Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program\n* Has started teclistamab treatment \\>14 days before intended screening visit.",{"count":385,"type":20},100,"The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA\u002FCD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.",[388,26],"Multiple Myeloma",[390,391,106,392,393],"Teclistamab","Tecvayli","Efficacy","Safety","2025-03-11",{"date":396,"type":39},"2025-03-12",{"date":398,"type":39},"2024-12-01",{"date":400,"type":20},"2027-09",{"name":402,"class":46},"Universitaire Ziekenhuizen KU Leuven",17,{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":21,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":424},"100581999","the-interplay-between-inborn-error-of-immunity-and-blood-disorders-unravelling-immune-defects-behind-common-haematological-diseases-100581999","NCT06857604","The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases","Inclusion Criteria:\n\n1. Patients age \\\u003C 25 years\n2. Patients with diagnosed autoimmune cytopenias (AIC), polyclonal lymphoproliferation (PL), lymphoma (ML), bone marrow failure, and myelodysplastic syndrome (BMF\u002FMDS) (see details below)\n3. Signed Informed Consent\n\nExclusion Criteria:\n\n1. Patients with Lymphoma secondary to HIV or transplant\n2. Patient with self-resolving or post-infective AICs","25 Years",{"count":269,"type":20},[23],"The universe of Inborn errors of Immunity (IEI) is rapidly expanding: their clinical spectrum is not only characterised by infections but often includes haematological complications. Moreover, an increasing number of \"IEI phenocopies\" due to somatic mutations in specific cell types are progressively being unveiled and complicate the genetic plot of IEI, which are therefore not only caused by germline mutations. However, these aspects have never been studied by large prospective studies.\n\nThis study aims to fill this gap by prospectively recruiting patients \\\u003C25 y\u002Fo with haematologic disorders that fall into one of the following 4 subgroups: autoimmune cytopenia (AICs), polyclonal lymphoproliferation (PL), monoclonal (malignant) lymphoproliferation (ML), bone marrow failure\u002Fmyelodysplasia (BMF\u002FMDS). Recruited subjects will undergo an extensive immunologic workup (extended immunophenotyping, cytokine and autoantibody dosage) together with genetic testing (NGS) to detect both germline and somatic variants. Bulk RNA sequencing will be performed either as functional validation of variants or to identify altered pathways in selected cases with inconclusive genetics. Patient advocacy organisations (PAOs) will be pivotal to assist patients' needs throughout the project and to raise awareness of predictive and yet unknown signs of IEI.\n\nThe study involves recruitment a total of almost 700 children over a 3-year period. Considering recent studies on AICs and BMF\u002FMDS, a global detection rate of 30% \"hidden\" IEI is expected, with higher rates in the AIC subgroup and lower ones for ML, given the complexity of lymphoma pathogenesis. New IEI candidate genes or new examples of IEI phenocopies are expected to be identified.\n\nThe immunological workup should detect early disease biomarkers or currently unknown molecular signatures of specific disorders. These may increase the chance of identifying an IEI in a specific subgroup and promptly address the patient to a targeted treatment or to hematopoietic stem cell transplantation, avoiding late complications, increasing patients' survival, and abating the economic burden of the disease on healthcare services. Finally, involvement of PAOs may foster patients' knowledge about their condition, increasing their compliance to disease follow-up and treatment and ameliorating their quality of life.",[26],"2025-02-27",{"date":417,"type":39},"2025-03-04",{"date":419,"type":39},"2024-11-15",{"date":421,"type":20},"2027-07",{"name":423,"class":46},"Meyer Children's Hospital IRCCS",7,{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":316,"enrollmentInfo":433,"targetDuration":4,"studyType":21,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":47},"100578315","phase-1-human-leukocyte-antigen-hla-mismatched-related-allogeneic-hematopoietic-stem-cell-transplantation-100578315","NCT06809699","Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective Single-arm Trial on Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","HIGHT","Inclusion Criteria:\n\n* Adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation with no available related human leukocyte antigen (HLA) identical sibling donors;\n* No available donor with HLA high-resolution typing ≥ 9\u002F10 or those who have difficulty finding donors due to urgent medical conditions;\n* No suitable HLA matching haploidentical donor available;\n* There is a suitable donor with mismatched HLA typing;\n* The subjects or their legal representatives shall sign an informed consent form before the start of the clinical study.\n\nExclusion Criteria:\n\n* Patients with severe liver and kidney function (alanine aminotransferase\\>2.5 times the upper limit of normal, blood creatinine\\>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (New York Heart Association (NYHA) III\u002FIV heart function, ejection fraction\\\u003C50%, severe obstructive or restrictive ventilation dysfunction);\n* Merge active infections;\n* Eastern Cooperative Oncology Group (ECOG) score ≥ 2 points;\n* Secondary tumors with merged activity;\n* Severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials;\n* Combine other allo HSCT contraindications.",{"count":434,"type":20},29,[58],"This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use human leukocyte antigen (HLA) mismatched donors. Ultimately, a HLA mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of these patients and truly enter the era of \"everyone has a donor\".",[26],[439,440,441],"Hematopoietic cell transplantation","HLA mismatch related","Hematologic diseases","2025-01-30",{"date":444,"type":39},"2025-02-05",{"date":446,"type":39},"2022-08-04",{"date":448,"type":20},"2027-10-31",{"name":450,"class":46},"He Huang",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":16,"minAge":459,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":462,"conditions":463,"keywords":466,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":47},"100454380","diagnosis-and-phenotype-characterisation-using-genomics-in-patients-with-inherited-bone-marrow-failure-ibmdx-study-100454380","NCT05196789","Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)","Diagnosis, Discovery and Novel Phenotype Characterisation Using Multimodal Genomics in Patients With Inherited Bone Marrow Failure and Related Disorders (IBMDx Study)","IBMDx","Inclusion Criteria:\n\n1. age ≥ 3 months\n2. able to give informed consent (or parent\u002Fguardian able to give informed consent)\n3. a clinicopathological diagnosis (or differential diagnosis) of inherited bone marrow failure syndrome or related disorder (IBMFS-RD) as per the study team\n\nExclusion Criteria:\n\n1. A clinicopathological diagnosis of an acquired bone marrow failure syndrome (including acquired aplastic anaemia and hypoplastic myelodysplastic syndrome) as per the study team\n2. Existing definitive genomic diagnosis for patient's haematological phenotype","3 Months",{"count":461,"type":20},350,"This project seeks to perform whole genome sequence (WGS) and whole transcriptome sequence (WTS) analysis on 350 patients with suspected inherited bone marrow failure syndromes and related disorder (IBMFS-RD) in order to increase the genomic diagnostic rate in IBMFS.",[464,465,26],"Inherited BMF Syndrome","Inherited Platelet Disorder",[467,468,469,470],"bone marrow failure syndrome","whole genome sequencing","hematological diseases","pancytopenia","2024-11-05",{"date":473,"type":39},"2024-11-07",{"date":475,"type":39},"2022-03-18",{"date":477,"type":20},"2025-12",{"name":479,"class":46},"Peter MacCallum Cancer Centre, Australia",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":487,"sex":16,"minAge":17,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":21,"phases":491,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":47},"100563227","phase-4-clinical-study-of-combined-platelet-transfusion-100563227","NCT06613425","Clinical Study of Combined Platelet Transfusion","Combined Platelet Transfusion:A Single-arm, Open, Prospective, Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* 1\\. Aged 18-65 years; 2. Disease treatment in the research hospital; 3. Applied for platelet transfusion therapy.\n\nExclusion Criteria:\n\n* 1\\. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy; 2. Without platelet transfusion indications; 3. Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion; 4. Gave up platelet transfusion therapy for any reason after enrollment; 5. Transferred or discharged from hospital for any reason before platelet transfusion after enrollment; 6. Did not receive combined platelet transfusion during the 6-month treatment period after enrollment",true,"65 Years",{"count":490,"type":20},86,[492],"PHASE4","Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.",[26],"2024-09-23",{"date":497,"type":39},"2024-09-26",{"date":499,"type":39},"2024-08-01",{"date":501,"type":20},"2025-10-28",{"name":503,"class":46},"The General Hospital of Western Theater Command",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":511,"enrollmentInfo":512,"targetDuration":4,"studyType":21,"phases":514,"briefSummary":515,"conditions":516,"keywords":526,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":47},"100536932","phase-1-a-study-to-evaluate-the-safety-pkpd-of-oricar-017-in-subjects-with-rrmm---rigel-study-100536932","NCT06271252","A Study to Evaluate the Safety, PK\u002FPD of (OriCAR-017) in Subjects With RR\u002FMM - RIGEL Study","A Phase I\u002FII, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed\u002FRefractory Multiple Myeloma.","Inclusion Criteria:\n\nCapable of giving signed informed consent\n\nSubjects aged 18 to 75 years (inclusive) at Screening (signing the ICF).\n\nExpected survival period is \\>12 weeks.\n\nDiagnosis of MM according to the IMWG criteria (2016 version).\n\nOne of the following criteria must be met:\n\nIf immunoglobulin (Ig)G type MM, then serum M protein \\>10 g\u002FL; if IgA, IgD, IgE or IgM type MM, then serum M protein \\>5 g\u002FL\n\nUrine M protein level \\>200 mg\u002F24 hour\n\nIf light chain type MM, then serum free light chain (sFLC) \\>100 mg\u002FL and K\u002Fλ FLC ratio is abnormal.\n\nExtramedullary lesions (\\>1 cm for diameter of the short axis).\n\nFor Phase I (dose-escalation) - Subjects who had received at least 3 prior lines of therapy, had previous exposure to BCMA-Ag+ therapies, and were refractory to the last line of therapy.\n\nFor Phase I (dose-expansion) and Phase II: Subjects with previous exposure to BCMA directed therapies including BCMA bispecific antibody (e.g., teclistamab), BCMA antibody directed conjugate (such as BLENREP), and BCMA-CAR-T (such as CARVYKT1TM)\n\nSubjects with adequate hematologic, renal, hepatic, pulmonary and cardiac function.\n\nSubject and partners willing to take and or use effective contraceptive measures until 2 years post IMP infusion.\n\nExclusion Criteria:\n\nPregnant or breastfeeding.\n\nSeropositive for history of human immunodeficiency virus Active Hepatitis B infection and or Hepatitis C infection\n\nKnown active or prior history of CNS involvement\n\nHistory of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) caused damage to terminal organs or required systemic application of immunosuppressive or other drugs in the past 2 years\n\nPresence of uncontrolled active infection\n\nSubjects who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of Screening Visit or who plan to undergo ASCT during the study.\n\nSubjects who received allogeneic stem cell therapy.\n\nAny condition that in the opinion of the Investigator, would interfere with evaluation of the IMP.\n\nReceived Bendamustine treatment 1 year prior to Screening Visit.","75 Years",{"count":513,"type":20},81,[58],"The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed\u002Frefractory multiple myeloma.\n\nRIGEL Study",[517,518,248,519,520,521,522,523,26,524,169,525,159,388],"Neoplasms, Plasma Cell","Neoplasms by Histologic Type","Hemostatic Disorders","Vascular Diseases","Cardiovascular Diseases","Paraproteinemias","Blood Protein Disorders","Hemorrhagic Disorders","Immunoproliferative Disorders",[527],"R\u002FR MM, CAR-T",{"date":529,"type":39},"2024-08-02",{"date":531,"type":39},"2024-04-03",{"date":533,"type":20},"2028-04-12",{"name":535,"class":211},"OriCell Therapeutics Co., Ltd.",{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":47},"100308768","rapid-analysis-of-infections-by-spectrometry-of-exhaled-breath-100308768","NCT03299608","Rapid Analysis of Infections by Spectrometry of Exhaled Breath","Exhaled Breath Analysis for Rapid Diagnosis in Opportunistic Respiratory Infections in Hematological Patients","RAISE","Inclusion Criteria:\n\n* Age ≥ 18y at start of study\n* One of the following diagnoses:\n\n  * De novo, refractory or relapsed AML\u002FMDS receiving intensive chemotherapy\n  * De novo, refractory or relapsed ALL\u002FT-lymphoblastic lymphoma receiving intensive chemotherapy\n  * Aplastic anemia requiring ATG therapy\n  * Any patient admitted for either autologous hematopoietic stem cell transplantation. Transplantation may not have been performed at time of enrolment.\n  * Any patient admitted with allogeneic hematopoietic stem cell transplantation within the last year, or planned during this admission.\n* Written informed consent obtained from the patient\n\nExclusion Criteria:\n\n* Hematological disease beyond the specified inclusion criteria\n* Signs of active respiratory infection\n* If previously enrolled: incomplete clearance of all signs of respiratory infection (both clinically, microbiologically and radiologically).",{"count":545,"type":20},246,"To quantify the diagnostic, prognostic and therapeutic value of spectrometric analysis of exhaled breath from hematological patients with respiratory infection.",[548,26],"Respiratory Tract Infections","2024-07-02",{"date":551,"type":39},"2024-07-03",{"date":553,"type":39},"2019-06-21",{"date":555,"type":20},"2025-09",{"name":402,"class":46},{"id":558,"slug":559,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":568,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":47},"100514726","hypnosis-and-virtual-reality-in-bone-marrow-examination-100514726","NCT05982249","Hypnosis and Virtual Reality in Bone Marrow Examination","Effectiveness of Recorded Hypnosis and Virtual Reality in Patients Undergoing a Bone Marrow Examination at the Hematology Unit","Inclusion Criteria:\n\n1. Age 18 or older\n2. Candidate for a BM examination at the hematology unit\n3. Ability to answer questionnaires in Hebrew, Arabic or Russian\n4. Informed consent form signing\n\nExclusion Criteria:\n\n1. Major hearing impairment\n2. Major visual impairment.",{"count":385,"type":20},[23],"The goal of this clinical trial is to compare the effects of hypnosis, virtual reality or their combination in patients undergoing a bone marrow procedure.\n\nThe main question it aims to answer is whether such interventions may relieve anxiety and other symptoms described by patients undergoing the procedure.\n\nBefore the bone marrow procedure and after being explained on the study and signing informed consent, the nurse will measure vital signs and participants will fill-out a 2-minutes' questionnaire and will be assigned to one of 3 groups:\n\n* Hearing a 7-minutes hypnotic script via earphones\n* Seeing and hearing virtual images and sounds via a virtual reality device during 7 minutes\n* None of these After these interventions or 10 minutes after assignation for patients not receiving intervention, patients will fill questionnaires again (about 5 minutes for filling the 2 questionnaires) and vital signs will be measured again. Then the bone marrow procedure will be performed. After the bone marrow procedure, the participants will fill-out another 2-minutes questionnaire and vital signs will be measured by the nurse.\n\nResearchers will compare hypnotic script, virtual reality, their combination or none of them to see if they can affect anxiety and other complaints in patients undergoing a bone marrow procedure.",[26],[569,570,106,571,572,573],"Bone marrow","Procedure","Hypnosis","Guided imagery","Virtual reality","2024-05-05",{"date":576,"type":39},"2024-05-07",{"date":578,"type":39},"2023-07-13",{"date":78,"type":20},{"name":581,"class":119},"Bnai Zion Medical Center",{"id":583,"slug":584,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":21,"phases":590,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":47},"100514727","naturopathic-pharmacological-consultation-in-hematology-100514727","NCT05982262","Naturopathic-pharmacological Consultation in Hematology","Naturopathic-pharmacological Consultation on the Use of Dietary Supplements in Patients With Hematological Diseases","Inclusion Criteria:\n\n1. Followed up for a hematological condition\n2. Ability to fill simple questionnaires in Hebrew, Russian or Arabic\n3. Indication for consultation:\n\n   1. Patient's request to expand knowledge about the use of DHS\n   2. Patient using DHS\n   3. Patient's desire to start using DHS\n   4. Patient that is interested in hearing about the use of DHS for his\u002Fher health condition\n   5. Medical or nursing team's recommendation to take DHS for medical treatment or to improve compliance with conventional treatment.\n\nExclusion Criteria:\n\nNone",{"count":385,"type":20},[23],"The goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions. The main question it aims to answer is whether such consultation can improve the safety of dietary and herbal supplements' use among these patients.\n\nParticipants will be asked to answer basic questions and fill-out questionnaire before and after meeting the consultation team. Some patients will be prescribed dietary and herbal supplements that may help relief some of the symptoms they describe, in a safe way and without interacting with the drugs they are taking.",[26],[594,595,106,393,596,597,598],"Dietary supplements","Herbal supplements","Consultation","Naturopath","Clinical pharmacist",{"date":576,"type":39},{"date":601,"type":39},"2023-06-15",{"date":603,"type":20},"2028-06",{"name":581,"class":119},{"id":606,"slug":607,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":11,"sex":16,"minAge":612,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":21,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":628},"100539465","molecular-characterizazion-and-biological-samples-centralisation-of-patients-affected-by-oncoematolofic-pathology-100539465","NCT06304194","Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology","Pilot Study to Assess the Feasibility of Centralizing Biological Samples at Onset and Relapse of Patients Referred to CROP Centers for Molecular Characterization of Oncohematologic Pathology","Inclusion Criteria:\n\n* Diagnostic suspicion of oncologic, hematologic or onco-immunologic disease\n* Suspected recurrence of oncological, onco-hematological, hematological or onco -immunological disease\n* Availability of biological material\n* Signature of informed consent\n* Age between 0 and 30 years\n\nExclusion Criteria:\n\n* Failure to sign the consent\n* Insufficiency of biological material for analysis\n* Patients with HIV, HCV and HBV seropositivity (HBSAg) due to biohazard and bias related to patients' immunological status that could influence gene expression and tumor behavior.","0 Years","30 Years",{"count":615,"type":20},340,[23],"Currently, the molecular characterization of onco-hematological, onco-immunological and hematological diseases, at onset or in relapse, of patients with suspected diagnosis afferent to the CROP centers, is done through centralization of biological samples at reference laboratories outside the Tuscany Region.\n\nIn order to preserve the wealth of clinical and biological data and use it for the benefit of present and future patients treated at the CROP centers, it is useful to evaluate the feasibility of centralization and molecular typing of mutations present in tumor tissue at the IRCCS AOU Meyer Oncohematology Laboratories and subsequently the analysis of clinical data from patients with diseases not under study to lay the foundations of a translational database that can then be associated with a biobank in the future.\n\nThis will enable a targeted contribution to pediatric oncohematology research, investing in possible targeted therapies with those patient subgroups that benefit from personalized disease assessment in mind. The goal of the project is to improve the regional infrastructure dedicated to organized data collection and management of biological samples in adequate time resulting in better and more comprehensive data collection.",[619,26],"Oncologic Disease","2024-03-04",{"date":622,"type":39},"2024-03-12",{"date":624,"type":39},"2023-07-05",{"date":626,"type":20},"2028-07-05",{"name":423,"class":46},3,{"id":630,"slug":631,"hasResults":11,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":11,"sex":16,"minAge":637,"maxAge":638,"enrollmentInfo":639,"targetDuration":4,"studyType":21,"phases":641,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":4},"100448955","phase-2-haploidentical-allogeneic-hematopoietic-stem-cell-transplantation-with-post-transplant-cyclophosphamide-for-rescuing-patients-with-graft-failure-100448955","NCT05126186","Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure","Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure: a Phase II Study","HaploRescue","Inclusion Criteria:\n\n* Aged from 3 to 70 years\n* All hematological diseases\n* Suffering from primary or secondary (within the 60 days post-transplantation) graft failure after a 1st allo-SCT\n* With usual criteria for allo-SCT:\n\n  * ECOG ≤ 2\n  * No severe and uncontrolled infection\n  * Cardiac function compatible with high dose of cyclophosphamide\n  * Adequate organ function: ASAT and ALAT ≤ 2.5N, total bilirubin ≤ 2N, creatinine clearance ≥30ml \u002F min\n* With identification of a haploidentical donor (brother, sister, parents, adult children or cousin)\n* Absence of donor specific antibody (DSA) detected in the patient with a MFI ≥ 1500 (antibodies directed towards the distinct haplotype between donor and recipient)\n* With health insurance coverage (bénéficiaire ou ayant droit).\n* Understand informed consent or optimal treatment and follow-up.\n* Contraception methods must be prescribed during all the duration of the research. Women and men of childbearing age must use contraceptive methods within 12 months and 6 months after the last dose of cyclophosphamide, respectively.\n* Having signed a written informed consent (2 parents for patients aged less than 18)\n\nExclusion Criteria:\n\n* Aged\\\u003C 3 years old and \\>70 years old\n* With uncontrolled infection\n* With Seropositivity for HIV or HTLV-1 or active hepatitis B or C defined by a positive PCR HBV or HCV and associated hepatic cytolysis\n* Yellow fever vaccine within 2 months before transplantation\n* Cancer in the last 5 years (except basal cell carcinoma of the skin or \"in situ\" carcinoma of the cervix)\n* Uncontrolled coronary insufficiency, recent myocardial infarction \\\u003C6 month, current manifestations of heart failure, uncontrolled cardiac rhythm disorders, ventricular ejection fraction \\\u003C50%\n* Heart failure according to NYHA (II or more)\n* Preexisting acute hemorrhagic cystitis\n* Renal failure with creatinine clearance \\\u003C 30ml \u002F min\n* Urinary tract obstruction\n* Pregnant (β-HCG positive) or breast-feeding\n* Who have any debilitating medical or psychiatric illness, which preclude understanding the inform consent as well as optimal treatment and follow-up\n* COVID vaccination or recent COVID disease \\\u003C3 months\n* Tutorship or curatorship\n* Contraindications to treatments used during the research","3 Years","70 Years",{"count":640,"type":20},35,[59],"Prognosis of patients with graft failure is dismal, and re-transplantation is the sole option for long-term survival. Currently, there is no consensus concerning therapeutic options in patients with primary or secondary (within the 60 days post-transplantation) graft failure and finding a new donor within an acceptable delay is challenging. Literature is poor on the subject while the overall survival of such patients is about 30% at 1 year. This situation thus represents today a very challenging unmet medical need.\n\nRecently, haploidentical (haplo) related donor Stem Cell Transplantation (haplo-SCT) have improved dramatically outcomes using T-cell replete grafts with administration of post-transplantation cyclophosphamide (PTCy, which targets alloreactive T cells generated early after an HLA-mismatched transplant, sparing regulatory T cells and leaving unaffected the non-dividing hematopoietic stem cells) and standard post-transplant immune suppression with a calcineurin inhibitor (CNI) and mycophenolate mofetil. Our group re-transplanted a patient who experienced two consecutive graft failures and was successfully managed through a third haplo-SCT from her son using PTCy. We then retrospectively collected and analyzed data from 26 primary graft failure patients transplanted between 2011 and 2017 in 15 centers on behalf of French Society for Stem Cell Transplantation and Cell Therapy (SFGM-TC). The study population consisted mainly of patients with primary or secondary (within the 60 days post-transplantation) graft failure who underwent haplo-SCT and received PTCy as graft-versus-host-disease prophylaxis. The 1-year overall survival was about 60% suggesting that this approach might be a valid option in this particular poor clinical situation but now need validation through a phase II multicenter, national, prospective cohort study.",[26,644,645],"Graft Failure","Allogeneic Hematopoietic Stem Cell Transplantation","2021-11-08",{"date":648,"type":39},"2021-11-18",{"date":650,"type":20},"2021-12-01",{"date":652,"type":20},"2026-12-01",{"name":181,"class":46},{"id":655,"slug":656,"hasResults":11,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":11,"sex":16,"minAge":662,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":665,"conditions":666,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":4},"100378613","response-to-chimeric-antigen-receptor-car-t-cells-therapy-in-patients-with-hematologic-malignancies-depending-on-tumor-characteristics-100378613","NCT04209829","Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics","Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies (Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma) Depending on Tumor Characteristics","BIOCART-HM","Inclusion Criteria:\n\n* patient with hematological malignancy (lymphoma, ALL, MM)\n* patient integrated into a CAR-T Cells program treatment\n* patient aged 15 years or over\n* patient having signed a written consent; as well as his legal representative if \\\u003C18 years old\n\nExclusion Criteria:\n\n* patient with other hematological malignancies than lymphoma, LAL or MM\n* patient's weight \\\u003C58 kg\n* patient treated with another treatment than CAR-T Cells\n* patient under tutorship or curatorship\n* patient not covered by a health system","15 Years",{"count":664,"type":20},600,"Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment.\n\nThe objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies",[26],"2019-12-20",{"date":669,"type":39},"2019-12-24",{"date":671,"type":20},"2019-12",{"date":673,"type":20},"2035-03",{"name":181,"class":46}]